{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"what-are-peptides-glp1-gut","urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-glp1-gut/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/what-are-peptides-glp1-gut/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-glp1-gut/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-glp1-gut/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-glp1-gut/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-glp1-gut/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-glp1-gut/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"what-are-peptides-glp1-gut","title":"What Are Peptides for GLP-1 Gut","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:43:31.819Z","body_excerpt":"## What's breaking down\n\nGLP-1 agonists are peptide-based drugs that mimic the natural GLP-1 hormone. They act on the gut by slowing gastric emptying and intestinal motility. This slows the movement of food through the digestive tract.\n\nIf gastric emptying slows markedly, food stays in the stomach longer. This can lead to feelings of fullness but also nausea or vomiting in many users. The same slowing can contribute to constipation or diarrhea depending on individual response and dose timing.\n\nThe core tradeoff is metabolic support versus potential gut signal suppression. The drug reduces appetite signals and caloric intake through gut effects. At the same time, it can suppress normal motility patterns that support comfortable digestion. Rapid weight loss from these drugs may also involve lean mass changes, which some studies link to overall body composition shifts rather than a unique drug effect beyond calorie restriction.\n\n## Why GLP-1 agonists (class) matters for you\n\n1. **Drug:** GLP-1 agonists (class) such as semaglutide.\n2. **What it does:** Provides metabolic benefit through appetite reduction and delayed gastric emptying, while carrying tradeoffs of gut slowing and potential muscle or lean mass loss during rapid weight reduction.\n3. **Therefore for you:** This drug suppresses appetite and motility signals to support weight and glucose control. It reduces mechanical load on the body through weight loss but trades off normal gut function, which can slow repair processes if side effects persist or if protein intake and activity drop.\n\nThe suppression helps metabolic repair pathways by lowering excess load. However, it may delay gut lining recovery if motility remains altered for long periods.\n\n## How these fit together\n\nSingle-compound focus. The GLP-1 class targets metabolic and gut motility layers directly. No additional peptides are scoped here, so the section centers on how the drug's suppression of signals supports one set of outcomes while requiring attention to the tradeoffs for overall balance.\n\n## What the evidence actually shows\n\nHuman trials document consistent gastrointestinal effects. A randomized controlled trial of semaglutide 1.0 mg weekly in women with PCOS and obesity used scintigraphy and found 37% solid meal retention at 4 hours versus none on placebo (P = 0.002). Half-emptying time increased from 118 to 171 minutes.\n\nSystematic reviews of randomized trials report higher rates of nausea, vomiting, diarrhea, and constipation versus placebo. One review of 39 trials showed class-wide increases in these events. Discontinuation due to adverse events reached 6.5% on active treatment versus 3.6% on placebo in another analysis of dozens of trials.\n\nOn muscle: some data indicate 15-40% of total weight loss may be lean mass, though one study in obese mice and humans found the loss was not disproportionate to fat loss and relative strength improved. Human observations note that resistance training plus protein intake helps preserve lean mass during GLP-1 use.\n\nGut microbiome shifts appear in animal models with agents like liraglutide increasing Akkermansia; human data remain limited.\n\n## What scientists say\n\nResearchers note that GLP-1 receptor agonists produce a class effect on gastrointestinal adverse events, with nausea as the most frequent reason for stopping treatment. Long-term trials have not confirmed earlier concerns about pancreatitis risk. Dose escalation speed influences tolerability. Strategies to preserve muscle during weight loss receive emphasis in recent commentary.\n\n## What people say on Reddit\n\nAnecdotal reports frequently mention ongoing nausea or constipation that improves with slower titration or dietary adjustments. Some users describe benefits in appetite control alongside frustration with slowed digestion. Individual variation is common; many tolerate the drugs well after initial weeks.\n\n## What people say on X\n\nPosts highlight real-world gastrointestinal symptoms such as nausea (around ","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c1","text":"Semaglutide 1.0 mg weekly increased 4-hour solid meal gastric retention to 37% versus 0% on placebo in a human RCT of women with PCOS and obesity.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Direct evidence of motility suppression mechanism in humans.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c2","text":"GLP-1 agonists increase risk of nausea, vomiting, diarrhea, and constipation versus placebo across multiple systematic reviews of RCTs.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Class effect documented in dozens of trials.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c3","text":"Lean mass can account for 15-40% of weight loss with GLP-1 therapies in some reports, though not always disproportionate to dietary restriction alone.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s3"],"source_status":"sourced","why_material":"Addresses muscle loss tradeoff central to rapid weight loss.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/36511825/","title":"Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity","quote":"Four hours after ingestion, semaglutide retained 37% of solid meal in the stomach compared to no gastric retention in the placebo group (P = 0.002).","summary":"Human RCT showing delayed gastric emptying with semaglutide.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"aedc856372e0a47cc6c8d6729c975c175dd9afdacd337832789ddb89382e4558"},{"id":"s2","type":"review","url":"https://www.jci.org/articles/view/194740","title":"Adverse effects of GLP-1 receptor agonists as glucose-lowering agents","quote":"A recent systematic review of 39 randomized controlled trials of GLP-1RAs showed a class effect of increased risks of nausea, vomiting, diarrhea and constipation compared with placebo.","summary":"Review summarizing GI adverse event data from RCTs.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"eeff3ed637595790835d4ce4bab732c664f832a288b9408bd4a8ffe85abbce44"},{"id":"s3","type":"review","url":"https://diabetes.org/newsroom/press-releases/new-glp-1-therapies-enhance-quality-weight-loss-improving-muscle-0","title":"New GLP-1 Therapies Enhance Quality of Weight Loss by Improving Muscle Preservation","quote":"lean body mass can account for up to 15-40% of total weight loss from GLP-1 therapies.","summary":"Discussion of body composition changes with GLP-1 use.","claim_ids":["c3"],"link_status":"ok","quote_status":"unverified","hash":"b3b9e201a336dddec772638ed3522dd4ed96968c0082bb0bd68b07c226a14d4e"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/36511825/","title":"Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity","quote":"Four hours after ingestion, semaglutide retained 37% of solid meal in the stomach compared to no gastric retention in the placebo group (P = 0.002).","summary":"Human RCT showing delayed gastric emptying with semaglutide.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"aedc856372e0a47cc6c8d6729c975c175dd9afdacd337832789ddb89382e4558"},{"id":"s2","type":"review","url":"https://www.jci.org/articles/view/194740","title":"Adverse effects of GLP-1 receptor agonists as glucose-lowering agents","quote":"A recent systematic review of 39 randomized controlled trials of GLP-1RAs showed a class effect of increased risks of nausea, vomiting, diarrhea and constipation compared with placebo.","summary":"Review summarizing GI adverse event data from RCTs.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"eeff3ed637595790835d4ce4bab732c664f832a288b9408bd4a8ffe85abbce44"},{"id":"s3","type":"review","url":"https://diabetes.org/newsroom/press-releases/new-glp-1-therapies-enhance-quality-weight-loss-improving-muscle-0","title":"New GLP-1 Therapies Enhance Quality of Weight Loss by Improving Muscle Preservation","quote":"lean body mass can account for up to 15-40% of total weight loss from GLP-1 therapies.","summary":"Discussion of body composition changes with GLP-1 use.","claim_ids":["c3"],"link_status":"ok","quote_status":"unverified","hash":"b3b9e201a336dddec772638ed3522dd4ed96968c0082bb0bd68b07c226a14d4e"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"what-are-peptides-glp1-gut","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":3,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":3,"claims_total":3,"sources":3,"anecdotal":0,"scientific":3,"user_reports":0,"questions":0,"evidence_ingests":0}}